相似文献
1
Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication.
Gut. 2006 Jan;55(1):137-8. doi: 10.1136/gut.2005.081117.
2
Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas.
J Clin Oncol. 2004 Sep 1;22(17):3491-7. doi: 10.1200/JCO.2004.10.087.
3
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.
J Pathol. 2007 Feb;211(3):296-304. doi: 10.1002/path.2117.
4
BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma.
Int J Hematol. 2008 Dec;88(5):516-523. doi: 10.1007/s12185-008-0187-z. Epub 2008 Oct 24.
5
MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.
J Pathol. 2005 Feb;205(3):293-301. doi: 10.1002/path.1715.
6
Etiology and therapy of Helicobacter pylori-associated gastric lymphomas.
Ann Hematol. 2003 Sep;82(9):535-45. doi: 10.1007/s00277-003-0677-2. Epub 2003 Jul 3.
7
Gastric lymphomas: genetics and resistance to H. pylori eradication.
Verh Dtsch Ges Pathol. 2003;87:116-22.
8
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).
Blood. 2005 Aug 1;106(3):1037-41. doi: 10.1182/blood-2005-01-0004. Epub 2005 Apr 21.
9
[Long-term outcome in patients with gastric MALT lymphoma after H. pylori eradication].
Nihon Rinsho. 2005 Nov;63 Suppl 11:516-9.
10
[H. pylori-negative gastric MALT lymphoma].
Nihon Rinsho. 2005 Nov;63 Suppl 11:625-8.
引用本文的文献
1
Role of non- gastric Helicobacters in -negative gastric mucosa-associated lymphoid tissue lymphoma.
World J Gastroenterol. 2023 Aug 28;29(32):4851-4859. doi: 10.3748/wjg.v29.i32.4851.
2
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.
Ther Adv Med Oncol. 2023 Jun 22;15:17588359231183565. doi: 10.1177/17588359231183565. eCollection 2023.
3
Recent Advances in the Genetic of MALT Lymphomas.
Cancers (Basel). 2021 Dec 30;14(1):176. doi: 10.3390/cancers14010176.
4
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.
Cancer Cell Int. 2021 Aug 19;21(1):436. doi: 10.1186/s12935-021-02143-z.
5
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.
Sci Rep. 2017 Oct 30;7(1):14333. doi: 10.1038/s41598-017-14102-8.
6
B-cell receptor signaling as a driver of lymphoma development and evolution.
Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20.
7
Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance.
Blood Cancer J. 2013 Jul 12;3(7):e125. doi: 10.1038/bcj.2013.22.
8
Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.
Exp Cell Res. 2010 Nov 15;316(19):3317-27. doi: 10.1016/j.yexcr.2010.05.004. Epub 2010 May 11.
9
Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.
Blood. 2009 Nov 5;114(19):4158-68. doi: 10.1182/blood-2008-12-192583. Epub 2009 Aug 20.
10
Pulmonary mucosa-associated lymphoid tissue lymphoma with strong nuclear B-cell CLL/lymphoma 10 (BCL10) expression and novel translocation t(1;2)(p22;p12)/immunoglobulin kappa chain-BCL10.
J Clin Pathol. 2007 Jun;60(6):727-8. doi: 10.1136/jcp.2006.041012. Epub 2006 Nov 10.
本文引用的文献
1
MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.
J Pathol. 2005 Feb;205(3):293-301. doi: 10.1002/path.1715.
2
MALT lymphoma: from morphology to molecules.
Nat Rev Cancer. 2004 Aug;4(8):644-53. doi: 10.1038/nrc1409.
3
Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.
Blood. 2003 Aug 1;102(3):1012-8. doi: 10.1182/blood-2002-11-3502. Epub 2003 Apr 3.
4
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication.
Gastroenterology. 2002 May;122(5):1286-94. doi: 10.1053/gast.2002.33047.
5
Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori.
Gut. 2001 Apr;48(4):454-60. doi: 10.1136/gut.48.4.454.
6
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Gut. 2001 Mar;48(3):297-303. doi: 10.1136/gut.48.3.297.
7
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32).
Nat Genet. 1999 May;22(1):63-8. doi: 10.1038/8767.
8
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.
Cell. 1999 Jan 8;96(1):35-45. doi: 10.1016/s0092-8674(00)80957-5.
9
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group.
Gastroenterology. 1997 Oct;113(4):1087-90. doi: 10.1053/gast.1997.v113.pm9322502.
Zotero 插件